Kurokoka Kanseri Yumwijima 2026: Kuvura Ubushinwa & Igiciro - Ibitaro Byegereye 

Kanseri y'umwijima kubaho mu 2026 hagaragaye iterambere ryinshi bitewe nubuvuzi bushya bwa neoadjuvant hamwe nubuyobozi bujyanye nubuvuzi buva mubushinwa. Ubushakashatsi buherutse gukorwa bwerekana ko imiti mishya ikoreshwa mbere yo kubagwa ishobora gukuba inshuro ebyiri abarwayi babaho nta ndwara zongeye kubaho, bigahindura urwego rw’ubuvuzi ku isi.

Iterambere muri Kanseri Yumwijima Igipimo cyo Kurokoka 2026

Imiterere ya kanseri ya hepatocellular (HCC) hamwe no kuvura cholangiocarcinoma intrahepatic (ICC) yahindutse cyane mu ntangiriro za 2026. Mu myaka ibarirwa muri za mirongo, kanseri y'umwijima yari ifitanye isano no kutamenya neza no kwiyongera cyane. Ariko, kanseri y'umwijima kubaho ibipimo ubu birimo gusobanurwa nigeragezwa rikomeye ry’amavuriro rituruka ku bigo nderabuzima bikomeye byo mu Bushinwa.

Inyigisho y'ingenzi yatangajwe muri Ikinyamakuru gishya cy’ubuvuzi muri Werurwe 2026 yerekana ihinduka rya paradigm. Iyobowe n’abashakashatsi bo mu bitaro bya Zhongshan byo muri kaminuza ya Fudan, iki kigeragezo cy’ibigo byinshi cyerekanye ko protocole yihariye ya neoadjuvant ishobora kwagura ubuzima bw’ibihe bitabaho kuva ku mezi 8.7 kugeza ku mezi 18. Ibi byerekana hafi inshuro ebyiri abarwayi bakomeza kutarwara kanseri nyuma yo kuvurwa.

Ubusobanuro bwaya makuru ntibushobora kuvugwa. Amateka, imyaka itanu yo kubaho nyuma yo kubagwa kanseri zimwe na zimwe z'umwijima zagaragaye hagati ya 25% na 40%. Kwinjiza imiti igamije kuvura no gukingira indwara mbere yo kubagwa birahinduka vuba "urwego rwo kwita" ku barwayi bujuje ibisabwa. Ubu buryo bugabanya ibibyimba cyane mbere yuko icyuma gikora ku ruhu, hamwe n’ibisubizo bifatika bigera kuri 55% mu bigeragezo.

Abashoferi b'ingenzi b'ubuzima bwiza

• Amasezerano ya Neoadjuvant: Gutanga ubuvuzi bwa sisitemu mbere yo kubagwa kugirango ibibyimba bigabanuke.
• Kwishyira hamwe kwa Immunotherapy: Gukoresha PD-1 / PD-L1 inhibitor kugirango ukoreshe sisitemu yumubiri kurwanya indwara ya microscopique.
• Intego Zisobanutse: Gukomatanya chimiotherapie hamwe na tyrosine kinase inhibitor (TKIs).
• Kumenya hakiri kare: Kunonosora neza biganisha kumahirwe yo gutabara mbere.

Iterambere ntabwo rigarukira gusa kubigeragezo. Muri Mutarama 2026, Komisiyo y’ubuzima y’Ubushinwa yarekuye u Amabwiriza y'ibanze ya Kanseri y'umwijima no gusuzuma (2026 Edition). Iyi nyandiko ikomatanya ibimenyetso byujuje ubuziranenge, harimo n’ubushakashatsi bw’umwimerere bwo mu gihugu bwasohotse mu binyamakuru mpuzamahanga byo hejuru, butanga ubuyobozi bwa tekinike bwemewe bw’ubuvuzi mu gihugu hose.

Ubushinwa bwo mu 2026 Amabwiriza y’ubuvuzi no guhuza impuguke

Isohora ry’amabwiriza 2026 ryerekana intambwe ikomeye mu kurwanya kanseri y’umwijima ku isi. Bitandukanye nibisubirwamo, verisiyo ya 2026 ikubiyemo mu buryo bweruye ibyagezweho kuva "intego yongeyeho ubudahangarwa". Irenze kurwego rworoshye rwa anatomique kugirango ishyiremo ibintu bishobora guteza ingaruka ku binyabuzima, byemeza ko ubuvuzi bujyanye n’umurwayi ku giti cye cyo kongera kubaho.

Inyandiko ya mugenzi ,. Impuguke zihuriweho nubuvuzi bwa Adjuvant buvura kanseri ya Hepatocellular (2026 Edition), yanashyizwe ahagaragara muri Shanghai. Iyobowe n’abashakashatsi Fan Jia na Zhou Jian, ubu bwumvikane bukemura ikibazo cyinangiye cyo kwisubiramo nyuma yo kubagwa, kikaba kibasira abarwayi 50% kugeza 70%. Ubwumvikane butanga uburyo bunoze bwo kumenya abarwayi “bafite ibyago byinshi-by-ibyago byinshi” bungukirwa cyane no kuvura indwara.

Gutandukanya Ingaruka zo Gusubiramo

Ubwumvikane bwa 2026 butangiza uburyo bunoze bwo gushyira mu byiciro ingaruka zishobora kubaho. Iri tondekanya ni ngombwa mu kumenya niba umurwayi akeneye ubuvuzi bukabije cyangwa bushobora gukurikiranwa buri gihe.

• Ibyago byo Kwisubiramo hakiri kare (years2 ans): Byasobanuwe nibintu nkibibyimba byinshi, diameter ntarengwa irenga cm 5, icyiciro cya Edmondson icyiciro cya III-IV, gutera mikorobe cyangwa macrovasulaire, lymph node metastasis, guturika kw'ibibyimba, hamwe no kudasanzwe kwa AFP cyangwa DCP nyuma yo kubagwa.
• Ibyago Byatinze Kugaruka (> Imyaka 2): Akenshi bifitanye isano nindwara ziterwa numwijima aho kuba ibinyabuzima byumwimerere.
• Ingamba nkeya: Abarwayi bafite ikibyimba kimwe cm5 cm kandi nta mikorobe itera bagirwa inama yo kwisuzumisha buri gihe aho kuvurwa bidatinze.

Uku gufunga neza kumatsinda "ibyago-by-ibyago byinshi" byemeza ko imiti ikomeye igenewe abayikeneye cyane, guhitamo itangwa ryumutungo no kugabanya ingaruka zidakenewe kubantu bafite ibyago bike. Amabwiriza ashimangira ko kuvura sisitemu yo kurwanya ibibyimba byinjiye mu cyiciro gishya aho uburemere bwacyo bwiyongereye cyane.

Ubuvuzi bwa Neoadjuvant: Uburyo bushya bwo Kwitaho

Igitekerezo cyo kuvura neoadjuvant - kuvura kanseri mbere y’ubuvuzi bwa mbere bwo kubaga - cyarangije mu bushakashatsi kugeza ku cya ngombwa mu 2026.Ikigereranyo cy’ibanze cyitabiriwe n’abarwayi 178 bo mu bitaro 11 byo mu Bushinwa cyatanze ibimenyetso bifatika bikenewe kugira ngo ubwo buryo bukorwe.

Muri iki kigeragezo, itsinda rimwe ryakiriye inshuro eshatu za chimiotherapie ya Gemox hamwe n’umuti ugamije kuvura hamwe n’umuti ukingira indwara. Itsinda rishinzwe kugenzura ryabazwe ako kanya, ibyo bikaba byari bisanzwe. Ibisubizo byari bitangaje: kubaho hagati yabantu batabayeho kubaho mumatsinda yo guhuza ibiyobyabwenge byari amezi 18, ugereranije namezi 8.7 gusa kubitsinda ryonyine.

Uburyo bwibikorwa

Intsinzi yiyi cocktail iri mubitero byayo byibasiye ikibyimba. Chimoterapi yica mu buryo butaziguye ingirabuzimafatizo zigabanya vuba. Imiti igamije kuvura ibuza inzira zihariye zitera gukura kw'ibibyimba na angiogenezi (imiyoboro y'amaraso). Imiti ikingira indwara, nka PD-1 inhibitor, ifasha sisitemu yumubiri yumubiri kumenya no gutera kanseri ishobora guhunga gutahura.

Mugabanye ikibyimba mbere yo kubagwa, abaganga barashobora kugera ku ntera isobanutse neza (R0 resection), ibyo bikaba bihanura cyane kubaho igihe kirekire. Byongeye kandi, kuvura micrometastase hakiri kare bibabuza gushinga ibirenge mubindi bice byumwijima cyangwa umubiri mugihe cyo kubaga.

Intambwe zo Gushyira mu bikorwa

• Intambwe ya 1: Gusuzuma no Gutegura: Kwerekana amashusho yose hamwe na biopsy kugirango yemeze HCC cyangwa ICC no kumenya icyiciro.
• Intambwe ya 2: Isuzuma ry'ingaruka: Suzuma igitero cy'amaraso, ingano y'ibibyimba, n'urwego rwa biomarker (AFP, DCP).
• Intambwe ya 3: Itsinda ryinshi (MDT) Isubiramo: Abaganga babaga, oncologiste, naba radiologiste bafatanya guhitamo ibyangombwa bya neoadjuvant.
• Intambwe ya 4: Ubuyobozi bwa Neoadjuvant: Mubisanzwe inzinguzingo 3 zo kuvura hamwe mubyumweru 6-9.
• Intambwe ya 5: Ongera usuzume: Kwerekana amashusho kugirango ugabanye ibibyimba kugabanuka nigisubizo.
• Intambwe ya 6: Kubaga kubaga: Gukomeza kubagwa niba ikibyimba kidashoboka kandi umurwayi arakwemerera.

Ubu buryo bwo gukora burimo kwakirwa n’ibitaro biyoboye bitari mu Bushinwa gusa ahubwo bigira ingaruka kuri protocole ku isi. Ubushobozi bwo guhindura imanza zidashobora gukemurwa nizindi zishobora gukemurwa hifashishijwe agaciro gakomeye kubarwayi bafite ibibyimba binini cyangwa bigoye.

Ingamba zo kuvura Adjuvant

Ndetse na nyuma yo kubagwa neza, ibyago byo kwisubiramo bikomeza kuba icyuho cyambere mugihe kirekire kanseri y'umwijima kubaho. Impuguke z’impuguke 2026 zitanga ibyifuzo birambuye kubijyanye no kuvura byiyongera, biva muburyo bwa "bumwe-bumwe-bwose" kubuvuzi bwuzuye.

Ubuvuzi bwa sisitemu muburyo bwa Adjuvant

Ubwumvikane bugaragaza iyinjizwa ry'ubuvuzi bwa sisitemu mu "gihe cyagenwe-cy'ubudahangarwa." Imibare yavuye mubushakashatsi burimo sintilimab na atezolizumab wongeyeho bevacizumab (gahunda ya “T + A”) byongereye uburemere bwo kuvura sisitemu mugice cya aduvant.

• Inzira yo Guhuza: Ibimenyetso byerekana ko guhuza imiti igenewe (nka donafenib) hamwe na immunotherapie (nka tislelizumab cyangwa toripalimab) bishobora kurushaho kunoza imenyekanisha ry’abarwayi bafite ibyago byinshi.
• Immunotherapy Monotherapy: Ku barwayi bafite ibyago byo kongera guhura n’ibibazo byinshi, ibizamini byo kwirinda indwara byonyine byagaragaje inyungu zikomeye mu kurokoka ubusa (RFS).
• Igihe rimara: Ubwumvikane burasaba amezi 6 kugeza 12 yo kuvura sisitemu yo kurwanya ibibyimba ku barwayi bafite ibyago byo hagati.

Ikigaragara ni uko monotherapy ya donafenib kubarwayi bafite ibyago byinshi yerekanye ko umwaka 1 wokubaho nta buzima busubira hafi 87%. Mubice byihariye byabarwayi, gahunda yo guhuza yatumye imyaka 1 yo kubaho muri rusange igera kuri 96.7%. Iyi mibare yerekana gusimbuka gukomeye kuva mumateka.

Ubuvuzi bwaho

Usibye imiti itunganijwe, ubuvuzi bwaho bugira uruhare runini mugukuraho indwara zisigaye. Amabwiriza 2026 arashimangira kandi akanonosora ibimenyetso bya Transarterial Chemoembolisation (TACE), Hepatic Arterial Infusion Chemotherapy (HAIC), hamwe nubuvuzi bwimirasire.

• TACE YIMBERE: Basabwe abarwayi bafite ibyago byinshi hafi ukwezi nyuma yo kubagwa, mubisanzwe bigizwe namasomo 1 kugeza 2.
• Adjuvant HAIC: Byasobanuwe neza kubarwayi bafite Microvascular Invasion (MVI). Nyuma yo gutangira HAIC ukoresheje gahunda ya FOLFOX itezimbere cyane RFS muri iri tsinda.
• Ubuvuzi bw'imirasire: Ubuvuzi bukabije bw’imishwarara (IMRT) bwashyizwe ku rutonde nkigikoresho cyingenzi cy’abarwayi bafite imipaka mito yo kubaga (cm1 cm), positivite ya MVI, cyangwa imiyoboro iva mu mitsi hamwe na trombus. Igabanya cyane ibyago byo kugaruka.

Izi nkeragutabara zagenewe kwibasira uburiri bwumwijima aho bishoboka cyane ko byagaruka, bikora nkurusobe rwumutekano hamwe nubuvuzi bwa sisitemu.

Sisitemu yo Kwiteza Imbere: BCLC 2026 Kuvugurura

Sisitemu yo kubika kanseri y’umwijima ya Barcelona (BCLC) iracyari uburyo bukoreshwa cyane ku isi. Ivugurura rya 2026 rikomeza ibice bitatu byingenzi byo gutegura, gutangaza, no kuvura ariko bizana urwego rufata ibyemezo byimpinduramatwara: urwego rwa CUSE.

Urwego rwo gufata ibyemezo

Ivugurura rya 2026 BCLC rihuza Ingorabahizi, Ukudashidikanya, Subjectivite, hamwe n Amarangamutima (CUSE) mu gufata ibyemezo byubuvuzi. Ibi byemera ko kuvura kanseri y'umwijima atari ugukurikiza algorithm ishingiye ku bunini bw'ikibyimba; bikubiyemo kuyobora urubuga rugoye rwibintu byihariye byabarwayi.

• Ingorabahizi: Kwemera indwara zitandukanye kandi zihari uburyo bwinshi bwo kuvura.
• Kutamenya neza: Gukemura ibibazo bidasobanutse no guhora byerekana ibimenyetso byubuvuzi.
• Subjectivite: Kubara itandukaniro ryabantu kugiti cyabo nibyifuzo byabavuzi nabarwayi.
• Amarangamutima: Urebye ibyakubayeho, ibiteganijwe, n'imyizerere yawe yitsinda ryita kumurwayi.

Uru rwego ruyobora Amakipe menshi (MDT) kugirango afate ibyemezo byubumenyi, bishingiye ku barwayi. Iremeza ko ubuvuzi "bwiza" ku mpapuro buhuza nukuri kwimibereho yumurwayi, indangagaciro, hamwe nububiko bwa physiologique.

Ibyifuzo byo kuvura byiciro

Kwinjizamo SBRT na TARE nk'uburyo bwo kuvura abarwayi bo mucyiciro cya mbere byagura agasanduku k'ibikoresho kubatari abakandida bo kubagwa cyangwa gukuraho kubera ibibyimba cyangwa ibiza. Hagati aho, ubwitonzi bujyanye no kuvura buri gihe mu cyiciro cya B bugaragaza ubushake bwo gukora imyitozo ishingiye ku bimenyetso, wirinda gukabya kugeza igihe amakuru menshi azaboneka.

Abaturage badasanzwe: Gutera no gukuraho

Ubwumvikane bwa 2026 kandi bukemura ibibazo bidasanzwe bikunze kugora gucunga kanseri yumwijima, cyane cyane guhinduranya umwijima no kuvura ablation.

Porotokole yo Guhindura Umwijima

Ku barwayi barimo guterwa umwijima, guhitamo gahunda yo gukingira indwara ni ngombwa. Ubwumvikane busaba gukoresha mTOR inhibitor (nka sirolimusi cyangwa everolimus) nkumugongo wa immunosuppression. Bitandukanye na inhibitori ya calcineurine, inhibitor ya mTOR byagaragaye ko ifite imiti igabanya ubukana, ishobora gufasha kugabanya ibyago byo kwandura kanseri nyuma yo guterwa.

Ibitekerezo byo kuvura

Mu gihe ibimenyetso byo mu rwego rwo hejuru bivura bivura nyuma yo gukuraho bikomeje kwegeranywa, ubwumvikane buvuga ko imiti igamije cyangwa ikingira indwara ishobora gufatwa ku barwayi bafite ibyago byinshi barimo gukurwaho. Urebye ko gukuraho akenshi bikoreshwa mubibyimba bito, umwirondoro wibyago uratandukanye no kwangwa gukomeye, ariko ihame ryo gukemura indwara ya micrometastique rikomeza kuba ingirakamaro kubafite imiterere mibi y’indwara.

Ubuyobozi bwuzuye hamwe nubuvuzi bwa virusi

Ikintu cyingenzi, akenshi cyirengagizwa muburyo bwo gutera imbere kanseri y'umwijima kubaho ni imiyoborere yindwara yumwijima. Amabwiriza 2026 ashimangira ko ubuvuzi bwibanze bwumwijima ari ngombwa kubarwayi bose.

Imiti igabanya ubukana

Ku barwayi barwaye virusi ya Hepatitis B (HBV) ifitanye isano na kanseri y'umwijima, gukoresha ubuzima bwabo bwose bugereranya nucleoside (nka tenofovir cyangwa entecavir) ni itegeko nyuma yo kubagwa. Kurwanya kwigana virusi bigabanya gucana, birinda umwijima kwangirika, kandi bigabanya ibyago byo kurwara kanseri ya de novo mubice byumwijima bisigaye.

Uruhare rwubuvuzi gakondo

Mu guhuza kugaragara kwubuvuzi gakondo nubu bugezweho, ubwumvikane busaba gukoresha granules ya Huaier nyuma yo kubagwa bikabije. Ubuvuzi bwa Clinical bwerekana ko ubu buryo bwo gutegura imiti y’Ubushinwa bushobora gufasha kubuza kubaho no gukomeza kubaho muri rusange, bigatanga ubundi buryo bwo kurinda abarwayi bakira.

Kunoza Porotokole

Ingamba zo gukurikirana zarazamuwe, cyane cyane ku matsinda yo hagati-yo hejuru. Icyifuzo ni ugukurikirana byibuze buri mezi atatu. Kurenga amashusho asanzwe (CT cyangwa MRI), umurongo ngenderwaho urerekana ko aho ibintu byemewe, tekinoroji ya biopsy yamazi nka Circulating Tumor Cells (CTC) hamwe na ADN ikwirakwiza ikibyimba (ctDNA).

• Gukurikirana CTC / ctDNA: Ibi bikoresho birashobora kumenya ibimenyetso bya molekuline yisubiramo amezi mbere yuko bigaragara kuri scan, bikemerera gutabara mbere.
• Gukurikirana Biomarker: Gukurikirana buri gihe urwego rwa AFP na DCP bikomeje kuba urufatiro rwo kugenzura.

Kubona Ibitaro hamwe n’ibigo bivura hafi yawe

Kubona ubuvuzi bwihariye ni ikintu kigena ingaruka zo kubaho. Abarwayi bashaka protocole iheruka, harimo na neoadjuvant rejime hamwe nubuvuzi buhanitse bwavuzwe haruguru, bagomba gushakisha ibigo bifite ishami ryihariye rya onkologiya ya hepatobiliary.

Ibyo gushakisha mubitaro

• Itsinda ryinshi (MDT): Menya neza ko ibitaro bifite gahunda ya MDT isanzwe aho abaganga, abaganga ba oncologue, radiologue, naba psychologue basuzumisha hamwe.
• Ikigeragezo cya Clinical Access: Ibitaro byo mu rwego rwo hejuru bikunze kwitabira ibizamini by’amavuriro ku isi cyangwa by’igihugu, bitanga imiti igezweho mbere yuko iboneka henshi.
• Ikoranabuhanga rigezweho: Kuboneka kwa SBRT, HAIC, hamwe nubuhanga buhanitse bwo kubaga nka laparoscopique cyangwa robot yumwijima.
• Umubare n'uburambe: Ibice byinshi cyane mubisanzwe bitanga raporo nziza yibibazo hamwe nubuzima bwo kubaga umwijima bigoye.

Mu Bushinwa, ibigo nk'ibitaro bya Zhongshan byo muri kaminuza ya Fudan, ibitaro bya kanseri byo mu Ishuri Rikuru ry'Ubuvuzi mu Bushinwa, n'ibitaro bya mbere bishamikiye kuri USTC biyoboye inshingano mu gushyira mu bikorwa aya mabwiriza 2026. Ku rwego mpuzamahanga, abarwayi bagomba gushaka NCI yagenwe na kanseri cyangwa ibitaro bya kaminuza bifite gahunda zikomeye za hepatobiliary.

Ibitekerezo Byibiciro no Kugerwaho

Nubwo iterambere ryubuvuzi muri 2026 ritanga icyizere, ikiguzi gikomeje guhangayikisha abarwayi benshi. Guhindura uburyo bwo kuvura indwara hamwe nubuvuzi bugamije bishobora kongera umutwaro wamafaranga yo kwivuza.

Ubwishingizi n'ubwishingizi

Mu Bushinwa, imiti myinshi isabwa, harimo imiti ya PD-1 yo mu ngo na TKIs, yashyizwe mu rutonde rw’ubwishingizi bw’ubuvuzi ku rwego rw’igihugu, igabanya cyane amafaranga yakoreshejwe mu mufuka ku barwayi. Iyi gahunda ni ngombwa mu kureba niba “igisubizo cy’igihugu” mu gukumira no kurwanya kanseri y’umwijima kigera ku baturage benshi.

Kwisi yose, ubwishingizi buratandukanye mubihugu hamwe nabatanga ubwishingizi. Abarwayi barashishikarizwa:

• Baza abajyanama mu by'imari y'ibitaro hakiri kare gahunda yo kuvura.
• Gutohoza gahunda zifasha abarwayi zitangwa namasosiyete yimiti.
• Shakisha ibyangombwa byo kwipimisha kwa muganga, akenshi bikubiyemo ikiguzi cyimiti yiperereza hamwe nibizamini bifitanye isano.

Ingaruka z'igihe kirekire mu bukungu

Ni ngombwa kureba ibiciro byo kwivuza murwego rwo kubaho igihe kirekire. Uburyo bwiza bwo kuvura neoadjuvant hamwe nubuvuzi bwirinda ko bwongera kubaho birashobora kugabanya ikiguzi cyose cyubuvuzi wirinda kuvura salvage ihenze, ibitaro inshuro nyinshi, hamwe nubuvuzi bwa palliative bujyanye nindwara zateye imbere, zisubiramo.

Icyerekezo kizaza hamwe nubushakashatsi bukomeje

Urwego rwo kuvura kanseri y'umwijima rugenda rutera imbere ku buryo butigeze bubaho. Amabwiriza ya 2026 nigishushanyo cyubumenyi bugezweho, ariko ubushakashatsi bukomeje gusunika imipaka. Ibyatanzwe vuba aha mu nama ngarukamwaka ya 2026 ASCO yaturutse mu bigo nkibitaro bya Zhongnan byerekana imipaka igaragara.

Ikoranabuhanga rishya

• Lattice Radiotherapy: Gucukumbura umutekano ningirakamaro bya Lattice Stereotactic Flash Radiotherapy kubibyimba binini byumwijima bidashoboka (cm10).
• Virusi ya Oncolytike: Igeragezwa ryicyiciro cya mbere ririmo gukora ubushakashatsi bwatewe inshinge zikurikirana za virusi ya oncolytike hamwe nizindi miti yibibyimba bikomeye.
• Kwinjiza Ibyuma Byuma: Ubushakashatsi kuri metabolite nka alfa-ketoglutarate itera ferroptose (urupfu ruterwa na selile) kugirango yongere amaradiyo muri kanseri yo mu gifu.

Ibi bishya byerekana ko ibisobanuro bya kanseri y'umwijima kubaho izakomeza gutera imbere. Kwishyira hamwe kwa metabolic reprogramming ubushishozi hamwe nubuhanga bwibisekuruza bizaza byizeza guhangana nuburyo butandukanye bwindwara.

Umwanzuro: Igihe gishya cy'amizero

Umwaka wa 2026 urahinduka mu ntambara yo kurwanya kanseri y'umwijima. Hamwe nogutangaza amabwiriza yigihugu agezweho, kwemeza imiti ivura neoadjuvant, hamwe no kunonosora uburyo bwo gutandukanya ibyago, abarwayi muri iki gihe bafite amahitamo meza kuruta mbere hose. Kwikuba kabiri-ibyabaye bitabaho kubaho mubigeragezo biheruka bitanga ibyiringiro bifatika aho habaye amahirwe make.

Uhereye ku buryo busobanutse bwo gukoresha "intego wongeyeho ubudahangarwa" kugeza ku micungire yuzuye y’indwara y’umwijima, inzira igana imbere irasobanutse. Intsinzi iterwa no kumenya hakiri kare, kubona ubuvuzi bwihariye butandukanye, no kubahiriza ibimenyetso bishya bishingiye kuri protocole. Mugihe ubushakashatsi bukomeje kwerekana ibibazo bya biologiya ya kanseri yumwijima, inzira ya kanseri y'umwijima kubaho ingingo zihamye hejuru, zihindura isuzuma rimwe ryica muburyo bukoreshwa, kandi akenshi burashobora gukira.

Abarwayi n'imiryango barashishikarizwa kwishora hamwe nitsinda ryabo ryita ku buzima, bakabaza amabwiriza agezweho, kandi bagashakisha inzira zose zivurwa. Ihuriro ry’inzobere mu buvuzi bw’Abashinwa n’ubufatanye mu bya siyansi ku isi byashyizeho urwego rukomeye rwo kurwanya kanseri y’umwijima, umurwayi umwe umwe.